3.37

1.81% 0.06

After Hours: 3.32 -0.05 -1.48%

Macrogenics Inc (MGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Macrogenics Inc stock is traded at $3.37, with a volume of 578.08K. It is up +1.81% in the last 24 hours and down -16.58% over the past month. Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Previous Close:

$3.31

Open:

$3.34

24h Volume:

578.08K

Relative Volume:

0.93

Market Cap:

$214.67M

Revenue:

$157.08M

Net Income/Loss:

$-70.36M

P/E Ratio:

-3.0317

EPS:

-1.1116

Net Cash Flow:

$-71.69M

1W Performance:

-5.07%

1M Performance:

-16.58%

6M Performance:

-4.26%

1Y Performance:

+99.41%

1-Day Range:

$3.30

$3.435

1-Week Range:

$3.19

$3.785

52-Week Range:

$1.29

$5.08

Macrogenics Inc Stock (MGNX) Company Profile

Name

Macrogenics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

301-251-5172

Address

9704 MEDICAL CENTER DRIVE, Rockville, MD

Employee

293

Twitter

@macrogenics

Next Earnings Date

2026-11-11

Latest SEC Filings

MGNX's Discussions on Twitter

Compare MGNX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MGNX Macrogenics Inc	3.37	214.67M	157.08M	-70.36M	-71.69M	-1.1116
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Upgrade	B. Riley Securities	Neutral → Buy
Sep-17-25	Resumed	Barclays	Overweight
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-10-24	Downgrade	Stifel	Buy → Hold
May-10-24	Downgrade	TD Cowen	Buy → Hold
Apr-26-24	Initiated	B. Riley Securities	Buy
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-20-23	Upgrade	Citigroup	Neutral → Buy
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy
Feb-11-22	Initiated	BMO Capital Markets	Outperform
Feb-04-22	Initiated	SMBC Nikko	Outperform
Nov-17-21	Resumed	Guggenheim	Buy
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Oct-15-21	Resumed	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-12-21	Upgrade	Barclays	Underweight → Overweight
Dec-22-20	Resumed	H.C. Wainwright	Buy
Aug-03-20	Downgrade	Citigroup	Buy → Neutral
Jun-01-20	Upgrade	Guggenheim	Neutral → Buy
May-26-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Underweight
Dec-19-19	Initiated	Cantor Fitzgerald	Overweight
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight
Nov-21-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-20-19	Resumed	Guggenheim	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Guggenheim	Neutral
Feb-07-19	Upgrade	Citigroup	Sell → Buy
Feb-07-19	Downgrade	Wedbush	Outperform → Neutral
Feb-06-19	Upgrade	Raymond James	Underperform → Mkt Perform
Feb-04-19	Downgrade	Citigroup	Neutral → Sell
Dec-10-18	Downgrade	Raymond James	Outperform → Underperform
Sep-10-18	Resumed	BTIG Research	Buy
May-31-18	Initiated	Evercore ISI	Outperform
Mar-05-18	Initiated	H.C. Wainwright	Buy
Mar-31-17	Initiated	Raymond James	Outperform

View All

Macrogenics Inc Stock (MGNX) Latest News

Oct 09, 2026

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research

Oct 09, 2026

Oct 08, 2026

MacroGenics insider exercises 8,000 options for MacroGenics stock - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026

MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead - AD HOC NEWS

Oct 07, 2026

Ezio Bonvini Executes 8,000 MacroGenics Stock Options at $2.60 Each - Kalkine Media

Oct 07, 2026

At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. - Stock Titan

Oct 07, 2026

Oct 05, 2026

MacroGenics stock faces October data after a Q2 revenue miss - AD HOC NEWS

Oct 05, 2026

Oct 01, 2026

MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS

Oct 01, 2026

MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS

Oct 01, 2026

Sep 30, 2026

Current ratio of MacroGenics, Inc. – HAN:M55 - tradingview.com

Sep 30, 2026

Sep 29, 2026

MacroGenics, Inc. Revenue Breakdown – HAN:M55 - tradingview.com

Sep 29, 2026

Sep 27, 2026

Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale - stocktitan.net

Sep 21, 2026

Sep 19, 2026

MacroGenics stock edges lower as biotech analysts highlight risk and upside - AD HOC NEWS

Sep 19, 2026

Sep 18, 2026

MacroGenics2026 Funding Rounds & List of Investors - tracxn.com

Sep 18, 2026

MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study - ChartMill

Sep 18, 2026

Sep 16, 2026

MGNX: Transformed structure, strong cash, and advancing antibody pipeline with key clinical milestones ahead - TradingView

Sep 16, 2026

MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline - Investing.com

Sep 16, 2026

Sep 12, 2026

MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits

Sep 12, 2026

Sep 10, 2026

MacroGenics CEO Eric Risser to present at H.C. Wainwright Global Investment Conference - Bitget

Sep 10, 2026

Sep 09, 2026

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha

Sep 09, 2026

MacroGenics (MGNX) Institutional Ownership 2026 - marketbeat.com

Sep 09, 2026

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance

Sep 09, 2026

Sep 08, 2026

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.

Sep 08, 2026

Aug 20, 2026